Product
CD19-CAR T-cells
1 clinical trial
4 indications
Indication
Acute Lymphoblastic LeukemiaIndication
RelapseIndication
RefractoryIndication
Pediatric Acute Lymphoblastic LeukemiaClinical trial
A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive LeukemiaStatus: Recruiting, Estimated PCD: 2026-06-01